352 related articles for article (PubMed ID: 14739125)
1. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib.
Clark RW; Sutfin TA; Ruggeri RB; Willauer AT; Sugarman ED; Magnus-Aryitey G; Cosgrove PG; Sand TM; Wester RT; Williams JA; Perlman ME; Bamberger MJ
Arterioscler Thromb Vasc Biol; 2004 Mar; 24(3):490-7. PubMed ID: 14739125
[TBL] [Abstract][Full Text] [Related]
2. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.
Millar JS; Brousseau ME; Diffenderfer MR; Barrett PH; Welty FK; Faruqi A; Wolfe ML; Nartsupha C; Digenio AG; Mancuso JP; Dolnikowski GG; Schaefer EJ; Rader DJ
Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1350-6. PubMed ID: 16574893
[TBL] [Abstract][Full Text] [Related]
3. HDL metabolism and CETP inhibition.
Barkowski RS; Frishman WH
Cardiol Rev; 2008; 16(3):154-62. PubMed ID: 18414186
[TBL] [Abstract][Full Text] [Related]
4. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.
Brousseau ME; Schaefer EJ; Wolfe ML; Bloedon LT; Digenio AG; Clark RW; Mancuso JP; Rader DJ
N Engl J Med; 2004 Apr; 350(15):1505-15. PubMed ID: 15071125
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels.
Davidson MH; McKenney JM; Shear CL; Revkin JH
J Am Coll Cardiol; 2006 Nov; 48(9):1774-81. PubMed ID: 17084249
[TBL] [Abstract][Full Text] [Related]
6. Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors.
Clark RW
Curr Opin Pharmacol; 2006 Apr; 6(2):162-8. PubMed ID: 16487747
[TBL] [Abstract][Full Text] [Related]
7. Cholesteryl ester transfer protein directly mediates selective uptake of high density lipoprotein cholesteryl esters by the liver.
Gauthier A; Lau P; Zha X; Milne R; McPherson R
Arterioscler Thromb Vasc Biol; 2005 Oct; 25(10):2177-84. PubMed ID: 16123327
[TBL] [Abstract][Full Text] [Related]
8. Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction.
Schaefer EJ; Asztalos BF
Am J Cardiol; 2007 Dec; 100(11 A):n25-31. PubMed ID: 18047849
[TBL] [Abstract][Full Text] [Related]
9. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation.
Inazu A; Brown ML; Hesler CB; Agellon LB; Koizumi J; Takata K; Maruhama Y; Mabuchi H; Tall AR
N Engl J Med; 1990 Nov; 323(18):1234-8. PubMed ID: 2215607
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cholesteryl ester transfer protein activity by JTT-705 increases apolipoprotein E-containing high-density lipoprotein and favorably affects the function and enzyme composition of high-density lipoprotein in rabbits.
Zhang B; Fan P; Shimoji E; Xu H; Takeuchi K; Bian C; Saku K
Arterioscler Thromb Vasc Biol; 2004 Oct; 24(10):1910-5. PubMed ID: 15331428
[TBL] [Abstract][Full Text] [Related]
11. Effect of inhibiting cholesteryl ester transfer protein on the kinetics of high-density lipoprotein cholesteryl ester transport in plasma: in vivo studies in rabbits.
Kee P; Caiazza D; Rye KA; Barrett PH; Morehouse LA; Barter PJ
Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):884-90. PubMed ID: 16373610
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.
Yvan-Charvet L; Matsuura F; Wang N; Bamberger MJ; Nguyen T; Rinninger F; Jiang XC; Shear CL; Tall AR
Arterioscler Thromb Vasc Biol; 2007 May; 27(5):1132-8. PubMed ID: 17322101
[TBL] [Abstract][Full Text] [Related]
13. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.
Barter PJ; Kastelein JJ
J Am Coll Cardiol; 2006 Feb; 47(3):492-9. PubMed ID: 16458126
[TBL] [Abstract][Full Text] [Related]
14. Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure.
Blasi E; Bamberger M; Knight D; Engwall M; Wolk R; Winter S; Betts A; John-Baptiste A; Keiser J
J Cardiovasc Pharmacol; 2009 Jun; 53(6):507-16. PubMed ID: 19455053
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.
McKenney JM; Davidson MH; Shear CL; Revkin JH
J Am Coll Cardiol; 2006 Nov; 48(9):1782-90. PubMed ID: 17084250
[TBL] [Abstract][Full Text] [Related]
16. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice.
Westerterp M; van der Hoogt CC; de Haan W; Offerman EH; Dallinga-Thie GM; Jukema JW; Havekes LM; Rensen PC
Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2552-9. PubMed ID: 16946130
[TBL] [Abstract][Full Text] [Related]
17. Where are we with high-density lipoprotein raising and inhibition of cholesteryl ester transfer for heart disease risk reduction?
Schaefer EJ; Asztalos BF
Curr Opin Cardiol; 2007 Jul; 22(4):373-8. PubMed ID: 17556892
[TBL] [Abstract][Full Text] [Related]
18. Thyroid hormone increases plasma cholesteryl ester transfer protein activity and plasma high-density lipoprotein removal rate in transgenic mice.
Berti JA; Amaral ME; Boschero AC; Nunes VS; Harada LM; Castilho LN; Oliveira HC
Metabolism; 2001 May; 50(5):530-6. PubMed ID: 11319713
[TBL] [Abstract][Full Text] [Related]
19. Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice.
Hansen MK; McVey MJ; White RF; Legos JJ; Brusq JM; Grillot DA; Issandou M; Barone FC
J Cardiovasc Pharmacol Ther; 2010 Jun; 15(2):196-202. PubMed ID: 20332533
[TBL] [Abstract][Full Text] [Related]
20. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.
Vergeer M; Bots ML; van Leuven SI; Basart DC; Sijbrands EJ; Evans GW; Grobbee DE; Visseren FL; Stalenhoef AF; Stroes ES; Kastelein JJ
Circulation; 2008 Dec; 118(24):2515-22. PubMed ID: 19029469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
